Metropolis Healthcare Limited — PPTs, 27-08-2026: Investor Presentation

Metropolis Healthcare posted solid FY26 results with revenue hitting ₹1,646 Cr (+23.6%), EBITDA ₹401 Cr (+23%), and PAT ₹191 Cr (+19%). This volume-led growth continued into Q1 FY27, with revenue up 17% YoY to ₹450 Cr and EBITDA margin at 25.2% (+210 bps YoY). B2C and rural segments were standout performers.

The company's strategy focuses on technology leadership, scientific differentiation, and profitable growth. Key drivers include expanding its physical network to 1,000 centers, growing its TruHealth wellness segment, and boosting specialty testing (especially genomics) to ~45% of revenue. Digital platforms and AI are enhancing efficiency and patient experience.

Recent developments include adding 295 service points and launching 36 new tests in Q1 FY27. Successful integration of past acquisitions, like Core, has bolstered capabilities and market presence. The company also completed a 3:1 bonus share issue in March 2026.

Management guides for FY27 revenue growth of 14-15% and a 100-150 bps EBITDA margin improvement, leveraging existing assets and specialty growth. Capex remains efficient at ~4% of revenue.